{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:46:38Z","timestamp":1791002798951,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"am","delay-in-days":323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-051204"],"award-info":[{"award-number":["INV-051204"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007863","name":"Rice University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CNS-1338099"],"award-info":[{"award-number":["CNS-1338099"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["INV-045468"],"award-info":[{"award-number":["INV-045468"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["C-1995"],"award-info":[{"award-number":["C-1995"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jconrel.2025.114191","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:09:42Z","timestamp":1757095782000},"page":"114191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Factors influencing monoclonal antibody pharmacokinetics across varying immune perturbations"],"prefix":"10.1016","volume":"387","author":[{"given":"Jonathon","family":"DeBonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg A.","family":"Igoshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Veiseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2025.114191_bb0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/molecules29030585","article-title":"The pharmaceutical industry in 2023: an analysis of FDA drug approvals from the perspective of molecules","volume":"29","author":"de la Torre","year":"2024","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114191_bb0010","first-page":"233","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antib Ther."},{"issue":"15","key":"10.1016\/j.jconrel.2025.114191_bb0015","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","article-title":"Designing antibodies as therapeutics","volume":"185","author":"Carter","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114191_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13318-024-00891-7","article-title":"Long-acting strategies for antibody drugs: structural modification, controlling release, and changing the administration route","volume":"49","author":"Wang","year":"2024","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114191_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly-neutralizing antibodies (bNAbs) for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"9","key":"10.1016\/j.jconrel.2025.114191_bb0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A monoclonal antibody for malaria prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114191_bb0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114191_bb0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/biomedicines11030765","article-title":"Recent advances in monoclonal antibody-based approaches in the management of bacterial sepsis","volume":"11","author":"Kharga","year":"2023","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.jconrel.2025.114191_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114191_bb0055","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/psp4.13303","article-title":"Pharmacokinetics-based design of subcutaneous controlled release systems for biologics","volume":"14","author":"Grosskopf","year":"2025","journal-title":"CPT Pharm. Syst. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114191_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejpb.2014.08.001","article-title":"Controlled release of therapeutic antibody formats","volume":"88","author":"Schweizer","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114191_bb0065","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/acs.molpharmaceut.4c00379","article-title":"Monoclonal antibody delivery using 3D printed biobased hollow \u03bcNe3dle arrays for the treatment of osteoporosis","volume":"21","author":"Uddin","year":"2024","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114191_bb0070","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1021\/acsmaterialslett.4c01164","article-title":"Carrier polymer-free dissolvable microneedles enable superhigh drug payload for percutaneous protein delivery","volume":"6","author":"Wang","year":"2024","journal-title":"ACS Mater. Lett."},{"key":"10.1016\/j.jconrel.2025.114191_bb0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2024.07.023","article-title":"Enhancing pancreatic cancer immunotherapy: leveraging localized delivery strategies through the use of implantable devices and scaffolds","volume":"373","author":"Minaei","year":"2024","journal-title":"J. Control. Release"},{"issue":"21","key":"10.1016\/j.jconrel.2025.114191_bb0080","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.7150\/thno.36514","article-title":"Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114191_bb0085","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.xphs.2018.11.038","article-title":"Alginate-based delivery systems for Bevacizumab local therapy: In Vitro structural features and release properties","volume":"108","author":"Ferreira","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.114191_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115300","article-title":"Therapeutic delivery systems for rheumatoid arthritis based on hydrogel carriers","volume":"208","author":"Chapa-Villarreal","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114191_bb0095","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.xphs.2016.02.031","article-title":"Mouse models for assessing protein immunogenicity: lessons and challenges","volume":"105","author":"Jiskoot","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.114191_bb0100","first-page":"38","article-title":"Role of animal models in biomedical research: a review","author":"Mukherjee","year":"2025","journal-title":"Lab. Anim. Res. [Internet]"},{"key":"10.1016\/j.jconrel.2025.114191_bb0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2019.08.010","article-title":"Domesticating the foreign body response: recent advances and applications","volume":"144","author":"Veiseh","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6317","key":"10.1016\/j.jconrel.2025.114191_bb0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/350423a0","article-title":"A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin \u03bc chain gene","volume":"350","author":"Kitamura","year":"1991","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/toxsci\/kfg243","article-title":"Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation","volume":"77","author":"Lam","year":"2004","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114191_bb0125","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","article-title":"Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies","volume":"8","author":"Avery","year":"2016","journal-title":"mAbs"},{"issue":"7","key":"10.1016\/j.jconrel.2025.114191_bb0130","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/0008-5472.CAN-17-1958","article-title":"Fc-mediated anomalous biodistribution of therapeutic antibodies in immunodeficient mouse models","volume":"78","author":"Sharma","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000619","article-title":"Fc\u03b3RII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion","volume":"8","author":"Oldham","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114191_bb0140","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1158\/1535-7163.MCT-18-0977","article-title":"Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody\u2013Drug Conjugate Via Fc\u2013Fc\u03b3R Interaction","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114191_bb0145","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"issue":"9","key":"10.1016\/j.jconrel.2025.114191_bb0150","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114191_bb0155","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/19420862.2016.1229721","article-title":"Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics","volume":"8","author":"Myzithras","year":"2016","journal-title":"mAbs"},{"issue":"7557","key":"10.1016\/j.jconrel.2025.114191_bb0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"issue":"7613","key":"10.1016\/j.jconrel.2025.114191_bb0165","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"issue":"6049","key":"10.1016\/j.jconrel.2025.114191_bb0170","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12793\/tcp.2018.26.1.10","article-title":"Development of R packages: \u2018NonCompart\u2019 and \u2018ncar\u2019 for noncompartmental analysis (NCA)","volume":"26","author":"Kim","year":"2018","journal-title":"Transl. Clin. Pharmacol."},{"issue":"1s","key":"10.1016\/j.jconrel.2025.114191_bb0180","doi-asserted-by":"crossref","first-page":"130s","DOI":"10.18433\/jpps30028","article-title":"Understanding the monoclonal antibody disposition after subcutaneous administration using a minimal physiologically based pharmacokinetic model","volume":"21","author":"Varkhede","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114191_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-021-04276-4","article-title":"Time-dependent population PK models of single-agent atezolizumab in patients with cancer","volume":"88","author":"Marchand","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114191_bb0190","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/psp4.12585","article-title":"Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants","volume":"10","author":"Chen","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114191_bb0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11095-020-02860-6","article-title":"Lymphatic distribution of etanercept following intravenous and subcutaneous delivery to rats","volume":"37","author":"Gao","year":"2020","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114191_bb0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10928-014-9372-2","article-title":"Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies","volume":"41","author":"Cao","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114191_bb0205","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114191_bb0210","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114191_bb0215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2016.09.004","article-title":"Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies","volume":"21\u201322","author":"Kamath","year":"2016","journal-title":"Drug Discov. Today Technol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114191_bb0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1015880819328","article-title":"Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration","volume":"7","author":"Supersaxo","year":"1990","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114191_bb0225","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/psp4.41","article-title":"A tutorial on target-mediated drug disposition (TMDD) models","volume":"4","author":"Dua","year":"2015","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114191_bb0230","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s11095-015-1703-5","article-title":"Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model","volume":"32","author":"Zhao","year":"2015","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0235","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964935","article-title":"Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings","volume":"13","author":"Germovsek","year":"2025","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114191_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"9","key":"10.1016\/j.jconrel.2025.114191_bb0245","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/psp4.12445","article-title":"Nonlinear mixed-effects model development and simulation using nlmixr and related R open-source packages","volume":"8","author":"Fidler","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114191_bb0250","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/psp4.12471","article-title":"Performance of the SAEM and FOCEI algorithms in the open-source, nonlinear mixed effect Modeling tool nlmixr","volume":"8","author":"Schoemaker","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114191_bb0255","author":"Fidler"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114191_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-11-research0046","article-title":"The genetic structure of recombinant inbred mice: high-resolution consensus maps for complex trait analysis","volume":"2","author":"Williams","year":"2001","journal-title":"Genome Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114191_bb0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5625\/lar.2017.33.2.119","article-title":"Use of C57BL\/6N mice on the variety of immunological researches","volume":"33","author":"Song","year":"2017","journal-title":"Lab. Anim. Res."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114191_bb0270","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1084\/jem.194.8.1151","article-title":"Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow","volume":"194","author":"Hao","year":"2001","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114191_bb0275","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R\u03b3null mice engrafted with mobilized human hemopoietic stem cells 1,2","volume":"174","author":"Shultz","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0280","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1770028","article-title":"Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies","volume":"12","author":"Datta-Mannan","year":"2020","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0285","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/antib14010002","article-title":"Rat as a predictive model for human clearance and bioavailability of monoclonal antibodies","volume":"14","author":"Robarge","year":"2024","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114191_bb0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: part 3\u2014introduction to pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114191_bb0295","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114191_bb0300","article-title":"Local controlled release of stabilized monoclonal antibodies","volume":"113743","author":"Chang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114191_bb0305","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jconrel.2021.12.010","article-title":"Intra-articular delivery of full-length antibodies through the use of an in situ forming depot","volume":"341","author":"Fayd\u2019herbe De Maudave","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114191_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.03.050","article-title":"Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies","volume":"323","author":"Chung","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114191_bb0315","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol J."},{"key":"10.1016\/j.jconrel.2025.114191_bb0320","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jconrel.2024.11.011","article-title":"Strategic delivery of rapamycin and ranibizumab with intravitreal hydrogel depot disrupts multipathway-driven angiogenesis loop for boosted wAMD therapy","volume":"377","author":"Jiang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114191_bb0325","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2024.08.023","article-title":"An in situ bioadhesive foam as a large intestinal delivery platform for antibody fragment to treat inflammatory bowel disease","volume":"374","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2025.114191_bb0330","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114191_bb0335","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jconrel.2021.09.006","article-title":"Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1","volume":"338","author":"Li","year":"2021","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500803X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500803X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:05:24Z","timestamp":1780477524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592500803X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":67,"alternative-id":["S016836592500803X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114191","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing monoclonal antibody pharmacokinetics across varying immune perturbations","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114191"}}